RPHM - דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים Reneo Pharmaceuticals, Inc

Reneo Pharmaceuticals (RPHM) minimizes commercial risks by developing small molecules for the therapy of rare mitochondrial pathologies in collaboration with scientific centers. The current stage of capital reallocation requires strict management oversight. High scaling potential is ensured by an intellectual monopoly on the drugs. This chart of trailing 12-month sales volume versus the previous year clearly demonstrates a trend where 0.00 expresses the metric's value today.
reneopharma.com (RPHM) - פילוחי מדדים ודוחות פיננסיים

This metric reflects the percentage change in total commercial revenues over a rolling twelve-month period, allowing for an assessment of business scaling rates relative to the previous year. By analyzing the trailing twelve-month (TTM) sales growth, an investor can observe the transition of Reneo Pharmaceuticals (RPHM) from investment funding to the monetization of developments in the field of rare mitochondrial pathology therapies, which determines the company's future capitalization potential.